Evidence map›Paper›PMID 40526312›Full record

ArticleDiscover oncology2025

RRP9 promotes prostate cancer metastasis and epithelial-mesenchymal transition through activation of the AKT/GSK3β/β-Catenin signaling pathway.

Zijian Da, Yadan Du, Yawen Chen, Mingxu Da, Fenghai Zhou

Abstract read
In one paragraph

Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Zijian DaThe First School of Clinical Medicine, Lanzhou University, Lanzhou, 730000, China.
Yadan DuThe First Clinical College, Gansu University of Traditional Chinese Medicine, Lanzhou, 730000, China.
Yawen ChenThe First Clinical College, Gansu University of Traditional Chinese Medicine, Lanzhou, 730000, China.
Mingxu DaThe First School of Clinical Medicine, Lanzhou University, Lanzhou, 730000, China.
Fenghai ZhouThe First School of Clinical Medicine, Lanzhou University, Lanzhou, 730000, China. ldyy_zhoufh@lzu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ribosomal RNA Processing 9 (RRP9) is a gene associated with ribosomal function, and studies have demonstrated that its expression is aberrantly regulated in various tumor types, correlating with tumor progression. However, the specific role and underlying mechanism of RRP9 in prostate cancer (PCa) remain largely unexplored. In this study, bioinformatics analysis revealed that RRP9 is upregulated in PCa and is significantly associated with poor prognosis and lymph node metastasis. Further experimental data demonstrated that RRP9 knockdown notably inhibited the metastasis, invasion, and epithelial-mesenchymal transition (EMT) of PCa. Conversely, overexpression of RRP9 activated the AKT signaling pathway, resulting in the phosphorylation of GSK3β at Ser9, which in turn prevented β-catenin degradation and promoted cell metastasis, invasion, and EMT. Rescue experiments demonstrated that SC79 effectively reversed the inhibitory effects of RRP9 knockdown on PCa. These findings highlight the potential role of RRP9 in promoting the malignant biological behaviors of PCa, providing new insights and potential therapeutic strategies for the treatment of the disease.

Indexed as

AKTEpithelial-mesenchymal transitionGSK3βMetastasisProstate cancerRRP9β-catenin

Identifiers

PMID40526312
PMCPMC12173975

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.